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Abstract
Background: The objective of this study is to assess anxiety, depression and panic disorders among patients
diagnosed with COPD and to investigate their correlation with disease severity, quality of life as well as tobacco use.
Methods: An observational study was performed between January and September 2014 among 60 patients
diagnosed with COPD. COPD staging according to GOLD criteria, while anxiety and depression were assessed using
Hospital Anxiety and Depression Scale and panic attacks were evaluated based on ICD 10 criteria.
Results: Almost 40% of the sample were smokers, the medium packs-years was 34.3 and the medium Fagerstrom
score was 7.5. Overall, mean Modified Medical Research Council Dyspnea Scale (mMRC) was 2.86, mean COPD
Assessment Test (CAT) score was 21.75 and study participants had 1.93 COPD exacerbations/year. Mean distribution of
anxiety and depression symptoms scores among COPD subjects was 10.65 ± 3.5 and 9.93 ± 3.8, respectively. Smokers
and ex-smokers had similar scores with regard to anxiety, depression or the presence of panic attacks. The results of
the bivariate correlations indicated associations between anxiety, depression, panic attacks and disease severity, as well
as poor quality of life of patients with COPD, regardless of their current tobacco use status.
Conclusions: In conclusion, the results of this study indicate that anxiety, depression and panic attacks were constant
characteristics among COPD patients- regardless of their current tobacco use.
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Introduction
In chronic obstructive pulmonary disease (COPD), a sys-
temic and disabling disorder, patients face a multitude of
symptoms, together with a psychological load in relation
with their disease [1, 2]. In recent years there is increas-
ing evidence that COPD patients often experience panic
attacks, anxiety and depression symptoms, especially in
severe disease stages; when anxiety and depression
occur, the risk of re-hospitalization and mortality is in-
creased [1–4]. Moreover there is growing recognition of
the fact that patients diagnosed with depression and bi-
polar disorders die prematurely due to concomitant
illnesses [1, 2]. Explanation for this bilateral interaction
lies in both symptom burden, functional impairment and
psychological changes that accompany a chronic condi-
tion such as COPD for example, and in maladaptive
health risk behaviors of the psychiatric patients [1, 2].
Symptoms of anxiety and depression are two of the
most common co-morbidities in people with COPD [5],
leading to significantly poor health outcomes, reduced
quality of life and significantly increased healthcare costs
[6]. In a retrospective, observational study, Gratziou and
colleagues reported that the prevalence of depression
among COPD patients with severe airway obstruction
(FEV1 < 50%) was 25% and they had a 2.5 times greater
risk of depression in comparison to healthy smokers [7].
High prevalence of depression is independently associ-
ated with smoking [8] and failure to quit [9]. Depression
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is also one of the withdrawal symptoms that predicts re-
lapse to smoking [10]. Patients with anxiety and depres-
sion often suffer from low self-confidence or self-
efficacy, which may lead to worsened disease related
coping [11] and poor self-care behaviors. Moreover, co-
existing addiction and psychiatric disorders significantly
decrease the cessation success rates in COPD smokers
and increase mortality among these patients [12].
Compared with persons without physical illness,
COPD patients have impaired quality of life [13–15].
That is why numerous diagnostic tools, like the COPD
Assessment Test (CAT) [16], St George’s Respiratory
Questionnaire (SGRQ) [17], Cough and Sputum Assess-
ment Questionnaire (CASA) [18] questionnaires, have
been developed recently, to assess how daily life of the
COPD patients is affected by their clinical condition.
In Romania, there are few data regarding the preva-
lence of COPD at national level. A study performed in
2012 estimated that 8.13% of population over 40 years
had this condition [19]. Even less is known about co-
morbid depression, anxiety and panic in Romanian
COPD patients, except for a few data available [19].
Hence, the first objective of this study is to assess anx-
iety, depression and panic disorders among smoking pa-
tients diagnosed with COPD. Secondly, we will
investigate their correlation with respiratory disease se-
verity and quality of life as well as with tobacco use.
Methods
Study population
An observational study was conducted between January
and September 2014, among patients diagnosed with
COPD from the Clinic of Pulmonary Diseases from Iaşi,
Romania. The study was approved by the local ethics
and management boards, based on volunteer consent
and permissions of participants and in respect to legisla-
tion for confidentiality of patient’s data use and
publishing.
The inclusion criteria of the subjects were:
– aged > 40
– a valid diagnosis of COPD according to the ERS-
ATS criteria for at least 12 months [20]
– had no history of psychiatric diagnosis other than
depression, anxiety, or panic attack
Tools and Measures
The subjects were asked to fill in a questionnaire which
assessed demographic data, medical history (with special
emphasis to cardiovascular co-morbidities), smoking sta-
tus, COPD staging and issues related to anxiety, depres-
sion and panic attacks as well as the impact of COPD on
their quality of life.
To define smoking, we used the standard Romanian
Smoking Cessation Guideline brief questionnaire asking
about past 12 months cigarettes consumption, number
of packs-years (PY), previous quit attempts and includ-
ing also nicotine dependence Fagerstrom test [21].
The 2011 “ABCD” GOLD guideline classification, was
used to stage COPD. This classification was still in use
in 2015 [20].
Anxiety and depression were screened by the Hospital
Anxiety and Depression Scale (HAD scale), whilst the
ICD 10 criteria served to confirm panic attacks. The
HAD scale is a 14 item scale that generates ordinal data.
Seven of the items relate to anxiety and seven to depres-
sion. Each item on the questionnaire is scored from 0 to
3 and this means that a person can score between 0 and
21 for either anxiety or depression, with scores catego-
rized as follows: normal (0–7), mild (8–10), moderate
(11–14) and severe (15–21) [22].
Impact of COPD on patients’ quality of life was deter-
mined by means of the COPD Assessment Test (CAT),
a patient-completed instrument, designed to provide a
simple and reliable measure of health status in COPD,
to both physician and patient [16].
CAT is a simple 8 item questionnaire that measures
the general impact of COPD on a patient’s health and
how this is changing over time; it is recommended for
use at any COPD visit. It contains questions about
COPD symptoms-cough, phlegm, tight chest - exercise
capacity and quality of sleep. It has a scoring range of 0-
40 and implications of the score need to be evaluated in
relation to a patient’s disease severity. Each patient gets
a score at each visit. Any difference or change of 2 or
more is considered meaningful for interpretation of
changes in COPD status.
Dyspnea was evaluated through Modified Medical Re-
search Council Dyspnea Scale (mMRC), a 0-4 gradually
assessing dyspnea index.
Statistical Analysis
Descriptive analysis were performed, while Pearson bi-
variate correlations were used to assess the relationship
between several variables. A statistically significant
threshold was considered a p < 0. 05. Data were analyzed
using SPSS 17 (SPSS Inc.).
Results
A total of 60 COPD patients (52 men and 8 women)
were enrolled in the study. Mean age was 62.2 years of
age. A percentage of 38.3% were smokers and 61.7%
were ex-smokers in the last 12 months). Among
smokers, the medium packs-years was 34.3 and the
medium Fagerstrom score was 7.5.
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Cardiovascular co-morbidity (hypertension, coronary
heart disease, acute myocardial infarction, heart failure)
was identified in a large proportion (43.3%) of subjects.
In terms of COPD severity, as classified by the GOLD
2011 criteria, 23.3% were in stage B, 41.7% in stage C
and 35% in stage D. The medium number of COPD ex-
acerbations/year was 1.9 and the medium number of se-
vere exacerbations was 0.8 per year. Overall, mean
mMRC was 2.86 ± 0. 92 SD, mean CAT score was 21.75
± 8.24 SD. Panic attacks, as judged by the ICD 10 cri-
teria were recognized in 43.3% of patients. Anxiety and
depression symptoms among COPD subjects were iden-
tified (10.65 ± 3.54 SD anxiety score, to 9.93 ± 3.80 SD
depression score respectively). A percentage of 16.7% of
participants had a normal score with regard to anxiety
(score 0–7), 40% had mild anxiety (score 8–10), 30%
moderate anxiety (score 11–14) and 13.3% severe anx-
iety (score 15–21). With regard to depression 23.3% had
a normal (score 0–7), 31.7% had mild depression (score
8–10), 35% moderate anxiety (score 11–14) and 10% se-
vere anxiety (score 15–21).
The results of the bivariate correlation analyses
showed no significant correlations between smoking sta-
tus (smokers vs ex-smokers) and either severity of
COPD, depression, anxiety, or panic attack. Heavy smok-
ing was not associated with COPD, depression, anxiety,
or panic attack, in our sample, while cardiovascular co-
morbidity history also did not influence HAD scale
scores or any panic event as no significant correlation
was distinguished.
On the other side, our results indicated that mMRC and
CAT scores had a significant correlation (r = 0.63, p ≤ 0.001),
while anxiety and depression (assessed by HAD scale) were
found to correlate significantly (r = 0. 54, p ≤ 0.001). More-
over, mMRC scores also obtained significant correlations
with the score for anxiety (r = 0.71, p ≤ 0.001), score for de-
pression (r = 0.34, p= 0.019), and panic events (r = 0.551,
p ≤ 0.001). Similarly, CAT’s scores had significant correla-
tions with: the: score for anxiety (r = 0.63, p ≤ 0.001), score
for depression (r = 0.45, p= 0.002), respectively with panic
attacks (r = 0.386, p= 0.008). Finally, COPD Gold stages
were correlated significantly with scores obtained for anxiety
(r = 0.307, p = 0.001).
Discussions
Our results indicated that anxiety and depression were
constant findings among our COPD patients, however
this was unrelated to tobacco use within this population.
In COPD, depression & anxiety prevalence estimates
vary widely, due either to the use of varied measurement
tools, or to the different degrees of illness severity across
studies. In stable COPD, the prevalence of clinical de-
pression ranges between 10 and 42%, while that of anx-
iety ranges between 10 and 19%. The risk of depression
is higher in patients with severe COPD compared to
control subjects and especially in oxygen-dependent pa-
tients, as well as in patients who have recently recovered
from an acute COPD exacerbation [23]. In another sys-
tematic review of 64 studies focusing on patients with
severe COPD, it was concluded that the prevalence of
depression ranged from 37 to 71%, and that of anxiety
from 50 to 75%, figures comparable to or higher than
prevalence rates in other severe somatic conditions, such
as cancer, AIDS, heart disease, and renal disease [24, 25].
Many patients with COPD experience panic attacks,
defined as episodes of intense anxiety accompanied by
symptoms of physical arousal. In this respect, consider-
ation needs to be given to differentiate a real panic dis-
order from a panic attack precipitated by exercise in
severe COPD patients, with a limited physical effort cap-
acity. To be diagnosed with a pure panic disorder, pa-
tients must experience recurrent panic attacks,
anticipatory anxiety about future attacks and some unex-
pected and unpredictable attacks (not always in situa-
tions inevitably causing dyspnea in COPD). The
prevalence of panic disorder in COPD has been esti-
mated as up to 10-times greater than the population
prevalence of 1.5–3.5% [26, 27].
In our study, statistic outcomes revealed significant
correlations of anxiety, depression and panic disorders
with COPD symptoms intensity and with related quality
of life, as assessed by mMRC and CAT. According to
data published in 2011, by Salerno and Carone [28],
there is a clear association between dyspnea and anxiety
or depression in COPD, and these symptoms are corre-
lated with and contribute to the severity of the chronic
obstructive pulmonary disease. Authors concluded fur-
ther studies are needed to better understand the rela-
tionship between psychological abnormalities and the
physiopathology of COPD and how this may be further
influenced by concurrent tobacco use.
Anxiety and depression are very often diagnosed in
COPD, even in the same time, with a significant impact
on patients’ quality of life and disease evolution. The
reason for developing these symptoms is not very well
known, but researchers have identified some frequently
associated factors, like: low body mass index, physical
disability, severe dyspnea, % of predicted FEV < 50%, co-
morbidities, poor quality of life, female gender, current
smoking, living alone and low social status [25]. Within
the current study, all patients were smokers or ex-
smokers and the scores for anxiety, depression and panic
attacks were similar for both categories.
Studies from other countries show that even though
health professionals are aware of the fact that symptoms
of anxiety and depression are two of the most common
co-morbidities in people with chronic obstructive pul-
monary disease [29], in fact, it seems, these COPD co-
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morbidities are not routinely managed in all pulmonary
diseases services, which leads to significantly poor health
outcomes, reduced quality of life and increased health-
care costs [30].
Similar with other studies, our results recommend that
clinicians caring for patients with COPD should screen for
psychological distress and manage this co-morbidity ap-
propriately [31]. According to current UK guidelines for
the management of anxiety and depression, psychological
treatment, pharmacological treatment or both in combin-
ation, are recommended as best practices [32, 33].
The limitations of the study are related to the rela-
tively small sample size which was over represented by
man participants, however this reflects the situation of
the hospitalized patients with COPD. Moreover, the
study did not include a control sample of people without
COPD in order to compare the score for anxiety, de-
pression and panic attacks between the groups, so the
comparisons are possible only with data obtained by
other studies.
Conclusions
In conclusion, the results of this study indicate that anx-
iety, depression and panic attacks were constant charac-
teristics among COPD patients, regardless of their current
tobacco use. These findings underline the necessity to
routinely screen anxiety, depression and panic in COPD
patients. Further research is needed to assess the potential
role of other tobacco related indexes with depression, anx-
iety, panick attacks among tobacco users with COPD.
Acknowledgements
The authors thank to all participants in the study.
Funding
No funding was provided for this study.
Availability of data and materials
Available after reasonable request.
Authors’ contributions
A. Trofor was involved in development of the study design and instrument,
supervised data collection efforts, performed data analyses and writing the
article. O.I. Pascal performed data collection and was involved in
development of the study design and instrument. D. Filipeanu performed
statistical analysis and helped with drafting manuscript. L.M. Lotrean, and L.
Trofor provided assistance in interpretation of results and writing the article.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics aproval and consent to participate
The study was conducted on hospitalized patients that signed an informed
consent at hospital admission, allowing performing medical procedures,
using personal data and educational activities, according to local hospital
management policy.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1“Grigore T. Popa” University of Medicine and Pharmacy Iasi, No 16
Universitatii Street, 700115 Iasi, Romania. 2“Iuliu Hatieganu” University of
Medicine and Pharmacy Cluj-Napoca, No 8 Victor Babeş Street, 400012
Cluj-Napoca, Romania. 3“Gheorghe Asachi” Technical University Iasi, No 67
Profesor Dimitrie Mangeron Street, 700050 Iași, Romania.
Received: 16 July 2016 Accepted: 3 April 2017
References
1. Chang CK, Broadbent M, Fernandes AC, Lee W, Hotopf M, Stewart R. All-
cause mortality among people with serious mental illness (SMI), substance
use disorders, and depressive disorders in southeast London: a cohort
study. BMC Psychiatry. 2011;10:77.
2. Wagena EJ, Arrindell WA, Wouters EF, van Schayck CP. Are patients with
COPD psychologically distressed? Eur Respir J. 2005;26:242–8.
3. Tetikkurt C, Ozdemir I, Tetikkurt S, Yılmaz N, Ertan N, Bayar N. Anxiety,
depression in COPD patients and correlation with sputum and BAL
cytology. Multidiscip Respir Med. 2011;6:226–31.
4. Dahlén I, Janson C. Anxiety and depression are related to the outcome of
emergency treatment in patients with obstructive pulmonary disease. Chest.
2002;122:1633–7.
5. Maurer J, Rebbapragada V, Borson S, et al. Anxiety and depression in COPD:
current understanding, unanswered questions, and research needs. Chest.
2008;134(4 Suppl):43S–56.
6. Naylor C, Parsonage M, McDaid D, Knapp M, Fossey M, Galea A. Long-term
conditions and mental health The cost of co-morbidities. The King’s Fund
and Centre for Mental Health. 2012.
7. Gratziou C, Florou A, Ischaki E, et al. Smoking cessation effectiveness in
smokers with COPD and asthma under real life conditions. Respir Med.
2014;108(4):577–83.
8. John U, Meyer C, Rumpf HJ, Hapke U. Smoking, nicotine dependence and
psychiatric comorbidity-a population-based study including smoking
cessation after three years. Drug Alcohol Depend. 2004;76(3):287–95.
9. Covey LS, Bomback A, Yan GW. History of depression and smoking
cessation: a rejoinder. Nicotine Tob Res. 2006;8(2):315–9.
10. Smith SS, Jorenby DE, Leischow SJ, et al. Targeting smokers at increased risk
for relapse: treating women and those with a history of depression.
Nicotine Tob Res. 2003;5(1):99–109.
11. Yohannes AM, Baldwin RC, Connolly MJ. Prevalence of depression and
anxiety symptoms in elderly patients admitted in post-acute intermediate
care. Int J Geriatr Psychiatry. 2008;23(11):1141–7.
12. Kupiainen H, Kinnula VL, Lindqvist A, et al. Successful Smoking Cessation in COPD:
Association with Comorbidities and Mortality. Pulm Med. 2012;2012:725024.
13. McSweeny AJ, Grant I, Heaton RK, et al. Life quality of patients with chronic
obstructive pulmonary disease. Arch Intern Med. 1982;142:473–8.
14. Prigatano GP, Wright EC, Levin D. Quality of life and its predictors in
patients with mild hypoxemia and chronic obstructive pulmonary disease.
Arch Intern Med. 1984;144:1613–9.
15. Yohannes AM, Baldwin RC, Connolly MJ. Depression and anxiety in elderly
outpatients with chronic obstructive pulmonary disease: prevalence, and
validation of the BASDEC screening questionnaire. Int J Geriatr Psychiatry.
2000;15:1090–6.
16. Glaxo Smith Kline. 2009. http://www.catestonline.org/english/indexEN.htm)
17. Celli BR, Cote CG, Lareau SC, Meek PM. Predictors of Survival in COPD: more
than just the FEV1. Respir Med. 2008;102 Suppl 1:S27–35. Cough and
Sputum Assessment Questionnaire.
18. Crawford B, Monz B, Hohifeld J, Roche N, Rubin B, Magnussen H, Niven C,
Ghafouri M, McDonald J, Tetziaff K. Development and validation of a cough
and sputum assessment questionnaire. Respir Med. 2008;102(11):1545–55.
doi:10.1016/jrmed.2008.06.009.Epub.
19. Magureanu IL, Furtunescu F. Importanta determinarii prevalentei BPOC.
Pneumologia. 2013;62:239–46.
20. Global Innitiative for Chronic Obstructive Lung Diseases (GOLD). Global
Strategy for the Diagnoses, Management and Prevention of Chronic
Pascal et al. Tobacco Induced Diseases  (2017) 15:23 Page 4 of 5
Obstructive Pulmonary Diseases. http://www.msc.es/organizacion/sns/
planCalidadSNS/pdf/GOLD_Report_2015_Apr2.pdf.
21. Trofor A, Mihaltan F, Todea D, Mihaicuta S, et al. Ghidul Societatii Romane
de Pneumologie: Ghid de renuntare la fumat si asistenta de specialitate a
fumatorului (GREFA). Iasi: Tehnopress; 2010.
22. Zigmond A. Snaith.Cum să te laşi de fumat. Recomandări, metode,
tratamente. Bucureşti: Ed. Tei; 2003.
23. Maurer J, Rebbapragada V, Borson S, Goldstein R, Kunik ME, Yohannes AM,
et al. Anxiety and Depression in COPD: Current Understanding, Unanswered
Questions, and Research Needs. Chest. 2008;134:43–56.
24. Lacasse Y, Rousseau L, Maltais F. Prevalence of depressive symptoms and
depression in patients with severe oxygen dependent chronic obstructive
pulmonary disease. J Cardiopulm Rehabil. 2001;21:80–6.
25. Kunik ME, Roundy K, Veazey C. Surprisingly high prevalence of anxiety and
depression in chronic breathing disorders. Chest. 2005;127:1205–11.
26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental
Disorders. Washington DC: American Psychiatric Association; 1994. p. 430–41.
27. Smoller J, Pollack M, Otto M. Panic anxiety, dyspnea, and respiratory disease.
Am J Respir Crit Care Med. 1996;154:6–7.
28. Salerno FG, Carone M. Anxiety and depression in COPD. Multidiscip Respir
Med. 2011;6:212–3.
29. Ng TP, Niti M, Tan WC, Cao Z, Ong KC, Eng P. Depressive symptoms and
chronic obstructive pulmonary disease: effect on mortality, hospital
admission, symptom burden, functional status and quality of life. Arch
Intern Med. 2007;167:60–7.
30. Naylor C, Parsonage M, McDaid D, Knapp M, Fossey M, Galea A. Long-term
conditions and mental health. The cost of co-morbidities. The Kings Fund
and Centre for Mental Health. 2012. https://www.kingsfund.org.uk/sites/files/
kf/field/field_publication_file/long-term-conditions-mental-health-cost-
comorbidities-naylor-feb12.pdf.
31. Baraniak A, Sheffield D. The efficacy of psychologically based interventions
to improve anxiety, depression and quality of life in COPD: a systematic
review and meta-analysis. Patient Educ Couns. 2011;83:29–36.
32. National Institute of Clinical Excellence. Depression in adults with a chronic
physical health problem. Treatment and management. National
Collaborating Centre for Mental Health. 2009. https://www.nice.org.uk/
guidance/CG91.
33. Generalised anxiety disorder and panic disorder in adults: management
Clinical guideline Published: 26 January 2011 nice.org.uk/guidance/cg113.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Pascal et al. Tobacco Induced Diseases  (2017) 15:23 Page 5 of 5
